ConductScience.org, home

Paper20101022

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.

Stein R and 7 others. Blood, 2010. Cited by 39 papers, by iCite.

Cite this record

ConductScience Library. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Papers, record 20101022. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20101022

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
PubMed
Journal
Blood
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
39
iCite
Relative citation ratio, by iCite
0.93
iCite
Revised in PubMed
2021-10-20
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stein RRhona
2Gupta PPankaj
3Chen XXiaochuan
4Cardillo TMThomas M
5Furman RRRichard R
6Chen SSusan
7Chang CHChien-Hsing
8Goldenberg DMDavid M

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
B-LymphocytesMajor topic
CytotoxinsMajor topic
Extracellular Signal-Regulated MAP KinasesMajor topic
HLA-DR AntigensMajor topic
Hematologic NeoplasmsMajor topic
MAP Kinase Kinase 4Major topic
MAP Kinase Signaling SystemMajor topic
Animals
Antigens, CD
Cell Line, Tumor
Drug Screening Assays, Antitumor
Enzyme Activation
Female
Humans
Mice
Mice, SCID

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P01 CA103985NCI NIH HHSUnited StatesP01CA103985PubMed and NIH
1P01-CA103985NCI NIH HHSUnited StatesP01CA103985PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01101594A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple MyelomaBackgroundClinicalTrials.gov
NCT01728207Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in20576816HLA-DR meets ERK.https://conductscience.org/library/papers/20576816

Source PubMed

Download CSV of comments and corrections

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111975981HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases.Hum Immunol2002https://conductscience.org/library/papers/11975981PubMed
219022808Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.Ann Rheum Dis2008https://conductscience.org/library/papers/19022808PubMed
39660836Identification of a novel inhibitor of mitogen-activated protein kinase kinase.J Biol Chem1998https://conductscience.org/library/papers/9660836PubMed
418799057Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement.Clin Exp Rheumatol2008https://conductscience.org/library/papers/18799057PubMed
510557099From receptors to stress-activated MAP kinases.Oncogene1999https://conductscience.org/library/papers/10557099PubMed
619011506A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.Medicine (Baltimore)2008https://conductscience.org/library/papers/19011506PubMed
79731049Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.Blood1998https://conductscience.org/library/papers/9731049PubMed
819000095Anti-CD20 treatment in primary Sjögren's syndrome.Scand J Immunol2008https://conductscience.org/library/papers/19000095PubMed
915174097Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma.J Cell Physiol2004https://conductscience.org/library/papers/15174097PubMed
1012101408Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.Nat Med2002https://conductscience.org/library/papers/12101408PubMed
1112153000In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.Leuk Lymphoma2002https://conductscience.org/library/papers/12153000PubMed
1217875789CD74: a new candidate target for the immunotherapy of B-cell neoplasms.Clin Cancer Res2007https://conductscience.org/library/papers/17875789PubMed
1312576316Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).Blood2003https://conductscience.org/library/papers/12576316PubMed
1411675350Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.Blood2001https://conductscience.org/library/papers/11675350PubMed
1515226177From the bench to the bedside: ways to improve rituximab efficacy.Blood2004https://conductscience.org/library/papers/15226177PubMed
166606682Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods1983https://conductscience.org/library/papers/6606682PubMed
1715297317Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.Blood2004https://conductscience.org/library/papers/15297317PubMed
1811843813Complement activation plays a key role in the side-effects of rituximab treatment.Br J Haematol2001https://conductscience.org/library/papers/11843813PubMed
1917071489A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.Leuk Lymphoma2006https://conductscience.org/library/papers/17071489PubMed
209841871Human mitogen-activated protein kinase kinase kinase mediates the stress-induced activation of mitogen-activated protein kinase cascades.Biochem J1998https://conductscience.org/library/papers/9841871PubMed

See all 54 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 39 citations.

PMIDTitleJournalYearIn PapersSource
42864501
Combined rituximab and magnesium acetyl taurate therapy attenuates neurodegeneration via ERK/c-JNK/P38MAPK signaling modulation in methylmercury-induced amyotrophic lateral sclerosis-like neurotoxicity.
Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42864501PubMed
41514561Fab Antibody Fragments to Dog Leukocyte Antigen DR (DLA-DR) Directly Suppress Canine Lymphoma Cell Line Growth In Vitro and in Murine Xenotransplant Model.Cancers (Basel)2025https://conductscience.org/library/papers/41514561PubMed
35563109Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma.Int J Mol Sci2022https://conductscience.org/library/papers/35563109PubMed
32934776Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.Oncotarget2020https://conductscience.org/library/papers/32934776PubMed
31561563An Antibody Specific for the Dog Leukocyte Antigen DR (DLA-DR) and Its Novel Methotrexate Conjugate Inhibit the Growth of Canine B Cell Lymphoma.Cancers (Basel)2019https://conductscience.org/library/papers/31561563PubMed
31443721ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.Cell Commun Signal2019https://conductscience.org/library/papers/31443721PubMed
29715484B cell MHC class II signaling: A story of life and death.Hum Immunol2019https://conductscience.org/library/papers/29715484PubMed
29475988HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection.J Immunol2018https://conductscience.org/library/papers/29475988PubMed
29022919DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.Cell Death Dis2017https://conductscience.org/library/papers/29022919PubMed
28932638The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.Oncoimmunology2017https://conductscience.org/library/papers/28932638PubMed
27203743The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.Oncotarget2016https://conductscience.org/library/papers/27203743PubMed
27128741Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen.Radiat Res2016https://conductscience.org/library/papers/27128741PubMed
27119356Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.Oncotarget2016https://conductscience.org/library/papers/27119356PubMed
26694167ASK1/JNK-mediated TAp63 activation controls the cell survival signal of baicalein-treated EBV-transformed B cells.Mol Cell Biochem2016https://conductscience.org/library/papers/26694167PubMed
25865044Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3.Oncotarget2015https://conductscience.org/library/papers/25865044PubMed
25773122A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.J Cancer Res Clin Oncol2015https://conductscience.org/library/papers/25773122PubMed
25639873The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Oncogene2015https://conductscience.org/library/papers/25639873PubMed
24670986Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.MAbs2014https://conductscience.org/library/papers/24670986PubMed
24037527The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies.Oncogene2014https://conductscience.org/library/papers/24037527PubMed
23090290Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.Cancer Immunol Immunother2012https://conductscience.org/library/papers/23090290PubMed

See all 25 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD22933PubTator's text mininghttps://conductscience.org/library/genes/933NCBI Gene
CD74972PubTator's text mininghttps://conductscience.org/library/genes/972NCBI Gene
KRT2054474PubTator's text mininghttps://conductscience.org/library/genes/54474NCBI Gene
MAP2K46416PubTator's text mininghttps://conductscience.org/library/genes/6416NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MAPK85599PubTator's text mininghttps://conductscience.org/library/genes/5599NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20101022

GET https://conductscience.org/api/papers/v1/20101022/references?page=2